REFERENCES
- Ross, R. (1999). Atherosclerosis: an inflammatory disease. N Engl J Med 340 (2): 115–126.
- Libby, P., Ridker, P.M., Maseri, A. (2002). Inflammation and atherosclerosis. Circulation 105 (9): 1135–1143.
- McDermott, D.H.(2000). Chemokines and their receptors in infectious disease. Springer Semin Immunopathol 22 (4): 393–415.
- Murphy, P.M., Baggiolini, M., Charo I,F. . (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52 (1): 145–176.
- Fong, A.M., Robinson, L.A., Steeber, D.A., Tedder, T.F., Yoshie, O., Imai, T., Patel, D.D.(1998). Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188 (8): 1413–1419.
- Imai, T., Hieshima, K., Haskell, C., . (1997). Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91 (4): 521–530.
- Umehara, H., Bollm, E.T., Okazaki, T., . (2001). Fractalkine and vascular injury. Trends Immunol 22 (11): 602–607.
- McDermott, D.H., Halcox, J.P., Schenke, W.H., . (2001). Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelialdysfunction and atherosclerosis. Circ Res 89 (5): 401–407.
- Moatti, D., Faure, S., Fumeron, F, . (2001). Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97 (7): 1925–1928.
- Ghilardi, G., Biondi, M.L., Turri, O. . (2004). internal rotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke; 35 (6): 1276–1279.
- Lavergne, E., Labreuche, J., Daoudi, M., . (2005) adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol 25 (4): 847–853.
- Hattori, H., Ito, D., Tanahashi, N., . (2005). T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. Neurosci Lett 374 (2): 132–135.
- Coll, B., Feinstein, S.B.(2008). Carotid intima-media thickness measurements: techniques and clinical relevance. Current Atherosclerosis Reports 10 (5): 444–450.
- Lorenz, M.W., Markus, H.S., Bots, M.L., . (2007). Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (4): 459–467.
- Prati, P., Tosetto, A., Vanuzzo, D., . (2008). Carotid intima media thickness and plaques can predict the occurrence of ischemic cerebrovascular events. Stroke 39 (9): 2470–2476.
- Norata, G.D., Garlaschelli, K., Ongari, M., . (2006). Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke 37 (6): 1558–1561.
- Combadiere, C., Potteaux, S., Gao, J.L., . (2003). Decreased atherosclerotic lesion formation in CX3CR1/ apolipoprotein E double knockout mice. Circulation, 107 (7): 1009–1013.
- Olliviera, V.,Faure, S., Tarantino, N., . (2003). Fractalkine/CX3CR1 production by human aortic smooth muscle cells impairs monocyte procoagulant and inflammatory responses. Cytokine 21 (6): 303–311.
- Myron, I., Cybulsky, Robert A., Hegele. The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. J Clin. Invest 111 (8): 1118–1120.